A global chocolate crisis looms, but scientists believe they can genetically engineer a fix – Quartz
Quartz |
A global chocolate crisis looms, but scientists believe they can genetically engineer a fix
Quartz But scientists say that climate in these regions shift dramatically by 2050 towards hotter, drier conditions not suitable for cocoa farming due, in part, to the diseases those changes would usher in, including “witches’ broom” and “frosty pod rot … CRISPR put to work to save chocolate from devastationUC Berkeley Chocolate is Going Extinct, But Scientists Have a Wild Plan to Save itInverse Could gene-editing save chocolate from extinction? Mars reveals its plan to create GM treats using cacao seeds that …Daily Mail OregonLive.com –The Independent –BGR –Markets Insider all 153 news articles » |
|
Mid-Day Market Update: SCANA Climbs Following Merger With Dominion Energy; Crispr Therapeutics Shares Slide
Benzinga … 9 percent to $12.14 after the company reported the termination of its merger deal with China’s Ant Financial, due to the CFIUS rejected the companies proposals related to protecting personal data. Shares of Atara Biotherapeutics Inc (NASDAQ: ATRA … |
Investor’s Business Daily |
Spark Therapeutics Prices First-Ever Gene Therapy At $850,000 …
Investor’s Business Daily Spark and GlaxoSmithKline are pricing the world’s first approved gene therapies at prices approaching $1 million. |
FiercePharma |
Inovio Amends Chinese Deal for Immunotherapy, Shares Up
Nasdaq Shares of Inovio Pharmaceuticals, Inc. INO ) have gained about 13.32%, after the company announced that it has entered into an amended agreement with Chinese partner – ApolloBio Corporation. Per the amended agreement, ApolloBio will have the exclusive … Inovio grabs $23M through HPV immunotherapy licensing deal with China’s ApolloBioFiercePharma Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in …Markets Insider Could Inovio Pharmaceuticals, Inc. (INO) Rise Even More? The Stock Had Another Big Increase TodayFrisco Fastball Market Exclusive all 50 news articles » |
Ovarian Cancer News Today |
Aivita Launches Phase 2 Trial of Dendritic Cell Immunotherapy for Ovarian Cancer
Ovarian Cancer News Today Aivita Biomedical has initiated a Phase 2 trial of a new kind of dendritic cell immunotherapy for certain types of ovarian cancer. The therapy uses a patient’s own dendritic cells, which are boosted to fight the tumor by exposure to tumor proteins. The … |
|
IDbyDNA, Locus Biosciences Partner on CDx for CRISPR …
GenomeWeb The next-generation sequencing test will be used to select patients for a clinical trial of Locus’ Pseudomonas aeruginosa antimicrobial product. Locus Biosciences and IDbyDNA Partner to Develop Companion …PR Newswire (press release) |